OverviewChartNewsTraderScreen

BNP Paribas Bonus Zert SNW 26.09..../  DE000PC2GNA4  /

EUWAX
6/24/2024  8:22:43 AM Chg.0.00 Bid10:00:38 PM Ask10:00:38 PM Underlying Strike price Expiration date Option type
109.07EUR 0.00% -
Bid Size: -		 -
Ask Size: -		 SANOFI SA INHABER ... - EUR 9/26/2024 Call
Newsfile Corp 6/24 HKSTP's Startup BioMap Secured Funding from HKIC for AI and Biotech Development
GlobeNewswire 6/21 Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s ...
GlobeNewswire 6/21 Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusi...
GlobeNewswire 6/20 Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
GlobeNewswire 6/18 Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Sm...
GlobeNewswire 6/11 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire 6/3 Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival ...
GlobeNewswire 5/31 Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
GlobeNewswire 5/31 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire 5/31 Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire 5/31 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire 5/31 Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire 5/30 Press Release: Sanofi completes acquisition of Inhibrx, Inc.
GlobeNewswire 5/27 Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire 5/23 CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
GlobeNewswire 5/21 Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire 5/20 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire 5/20 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire 5/20 Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire 5/13 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire 5/13 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire 5/13 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
TeleTrader 5/10 Novavax skyrockets 213.5% in premarket, highest in 16 months
TeleTrader 5/10 Novavax soars 39.6% in premarket after Sanofi license deal
GlobeNewswire 5/10 Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...